RxDoctor Payments Data

Joseph Koenigsmark

Addiction Medicine · Shepherdsville, KYNPI 1437214731

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $696, 2.9 times the $237 reported in 2019.

$3,346in general payments, 2019–2025

Across 195 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$684
  • AbbVie$625
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$413
  • Orexo US, Inc.$409
  • Indivior Inc.$270
  • Vanda Pharmaceuticals Inc.$196
  • plus $750 from 18 others

What the payments were for

  • Food & beverage$3,346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,346 in reported general payments places this provider in the 85th percentile of 40 addiction medicine providers in Kentucky.

See all addiction medicine providers in Kentucky

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl135$24,070
VraylarCariprazine Hcl14$19,099
ZubsolvBuprenorphine Hcl/Naloxone Hcl11$18,113
SuboxoneBuprenorphine Hcl/Naloxone Hcl14$6,668
Buprenorphine Hcl62$2,130
Gabapentin25$293
Clonazepam44$287
Lamotrigine20$181
Alprazolam13$83
Buspirone Hcl14$14

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$625$19,09914 claims
Orexo US, Inc.Zubsolv$409$18,11311 claims
Indivior Inc.Suboxone$270$6,66814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 40 addiction medicine providers in Kentucky.

Other addiction medicine in Shepherdsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →